RealTime Dynamix™: Multiple Sclerosis US Q3 2017 Spotlight

As previously predicted, Genentech’s Ocrevus trial and share have increased significantly over the past quarter, positioning the new market entrant as second only to Biogen’s Tysabri in the mAb DMT class, according to the most recent quarterly update by Spherix Global Insights. Yet, barriers do exist, including insurance coverage among Ocrevus user.

Click the button below to view highlights from this report:

Download Report Spotlight

Following last quarter’s surprising contraction, the oral DMT class (Sanofi Genzyme’s Aubagio, Novartis’ Gilenya, Biogen’s Tecfidera) again shows signs of growth as oral DMTs are increasingly viewed as appropriate options for treatment-naïve MS patients — putting competitive pressure on the traditional first-line injectable DMTs. Nevertheless, Aubagio, the oral DMT preferred by the fewest neurologists, has been struggling to continue the notable share surge observed throughout 2016 although neurologists remain optimistic about the brand.

Click the button below to view highlights from this report:

Download Report Spotlight II

2017-10-17T19:39:43+00:00